PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 32323054-0 2020 Dexmedetomidine had neuroprotective effects on hippocampal neuronal cells via targeting lncRNA SHNG16 mediated microRNA-10b-5p/BDNF axis. Dexmedetomidine 0-15 brain-derived neurotrophic factor Rattus norvegicus 127-131 32655312-0 2020 Dexmedetomidine Attenuates Neurotoxicity in Developing Rats Induced by Sevoflurane through Upregulating BDNF-TrkB-CREB and Downregulating ProBDNF-P75NRT-RhoA Signaling Pathway. Dexmedetomidine 0-15 brain-derived neurotrophic factor Rattus norvegicus 104-108 32655312-9 2020 Dexmedetomidine could reduce synaptic plasticity decline in developing rats induced by sevoflurane, through downregulating the proBDNF-p75NTR-RhoA pathway and upregulating BDNF-TrkB-CREB. Dexmedetomidine 0-15 brain-derived neurotrophic factor Rattus norvegicus 130-134 32323054-10 2020 DEX inhibited miR-10b-5p expression but increased SHNG16 and BDNF levels with a dosage effect. Dexmedetomidine 0-3 brain-derived neurotrophic factor Rattus norvegicus 61-65 32323054-13 2020 In conclusion, DEX exerts neuroprotective in ischemic stroke via improving neuron damage, the underlying mechanism may be upregulating SHNG16 and BDNF via sponging miR-10b-5p. Dexmedetomidine 15-18 brain-derived neurotrophic factor Rattus norvegicus 146-150 30483749-0 2019 Dexmedetomidine attenuates the toxicity of beta-amyloid on neurons and astrocytes by increasing BDNF production under the regulation of HDAC2 and HDAC5. Dexmedetomidine 0-15 brain-derived neurotrophic factor Rattus norvegicus 96-100 31220473-0 2019 Dexmedetomidine protects neurons from kainic acid-induced excitotoxicity by activating BDNF signaling. Dexmedetomidine 0-15 brain-derived neurotrophic factor Rattus norvegicus 87-91 31220473-8 2019 Dexmedetomidine ameliorated KA-induced apoptosis, and this neuroprotective effect was accompanied by inhibited the KA-induced caspase-3 expression as well as MAPKs phosphorylation, and reversed Bcl-2 down-expression, coupled with increased Nrf2, BDNF and TrkB expression in KA-treated rats. Dexmedetomidine 0-15 brain-derived neurotrophic factor Rattus norvegicus 246-250 31220473-9 2019 The results suggest that dexmedetomidine protected rat brains from KA-induced excitotoxic damage by reducing glutamate levels, suppressing caspase-3 activation and MAPKs phosphorylation, and enhancing Bcl-2, Nrf2, BDNF and TrkB expression in the hippocampus. Dexmedetomidine 25-40 brain-derived neurotrophic factor Rattus norvegicus 214-218 30483749-10 2019 However, Dex reversed the Abeta-induced deacetylation of histone H3 and thus, increased BDNF production. Dexmedetomidine 9-12 brain-derived neurotrophic factor Rattus norvegicus 88-92 30483749-12 2019 These results suggested that the protective effect of Dex against Abeta is particularly relevant to BDNF. Dexmedetomidine 54-57 brain-derived neurotrophic factor Rattus norvegicus 100-104 29872336-1 2018 Background: Dexmedetomidine (DEX) could have an analgesic effect on pain transmission through the modulation of brain-derived neurotrophic factor (BDNF). Dexmedetomidine 12-27 brain-derived neurotrophic factor Rattus norvegicus 112-145 29571823-3 2018 Therefore we hypothesize the promoting neurogenesis of Dex linked to stimulating BDNF and subsequent p-MPAK production in a rat model of POCD. Dexmedetomidine 55-58 brain-derived neurotrophic factor Rattus norvegicus 81-85 29571823-7 2018 As expected, Dex rescued the associated cognitive impairment and inflammatory changes, as well as up-regulated expression of BDNF, PKA, p-CREB/CREB and following p-P38-MAPK regulation. Dexmedetomidine 13-16 brain-derived neurotrophic factor Rattus norvegicus 125-129 31245956-1 2019 OBJECTIVE: To investigate the effects of dexmedetomidine (DEX) on hippocampal neuron development process and the expressions of molecules in brain-derived neurotropic factor (BDNF)-tyrosine receptor kinase B (TrkB) signaling pathway in neonatal rats. Dexmedetomidine 41-56 brain-derived neurotrophic factor Rattus norvegicus 175-179 31245956-1 2019 OBJECTIVE: To investigate the effects of dexmedetomidine (DEX) on hippocampal neuron development process and the expressions of molecules in brain-derived neurotropic factor (BDNF)-tyrosine receptor kinase B (TrkB) signaling pathway in neonatal rats. Dexmedetomidine 58-61 brain-derived neurotrophic factor Rattus norvegicus 141-173 31245956-9 2019 CONCLUSION: 50 mumol/L DEX has a certain effect on rat hippocampal neurons, which may be achieved by up-regulating the expression of BDNF and the phosphorylation level of N-methyl-D-aspartate receptor. Dexmedetomidine 23-26 brain-derived neurotrophic factor Rattus norvegicus 133-137 29872336-1 2018 Background: Dexmedetomidine (DEX) could have an analgesic effect on pain transmission through the modulation of brain-derived neurotrophic factor (BDNF). Dexmedetomidine 12-27 brain-derived neurotrophic factor Rattus norvegicus 147-151 29872336-1 2018 Background: Dexmedetomidine (DEX) could have an analgesic effect on pain transmission through the modulation of brain-derived neurotrophic factor (BDNF). Dexmedetomidine 29-32 brain-derived neurotrophic factor Rattus norvegicus 112-145 29872336-1 2018 Background: Dexmedetomidine (DEX) could have an analgesic effect on pain transmission through the modulation of brain-derived neurotrophic factor (BDNF). Dexmedetomidine 29-32 brain-derived neurotrophic factor Rattus norvegicus 147-151 29872336-8 2018 Results: In the first part of our experiment, the results revealed that the BDNF/TrkB-KCC2 signal plays a critical role in the development of SMIR-evoked PPSP; the second part showed that intraperitoneal administrations of 40 microg/kg DEX at 15 min presurgery and 1 to 3 days post-surgery significantly attenuated SMIR-evoked PPSP. Dexmedetomidine 236-239 brain-derived neurotrophic factor Rattus norvegicus 76-80 29872336-11 2018 Conclusion: The results of our study indicated that DEX attenuated PPSP by restoring KCC2 function through reducing BDNF/TrkB signal in the spinal dorsal horn in rats, which provides a new insight into the treatment of chronic pain in clinical postsurgical pain management. Dexmedetomidine 52-55 brain-derived neurotrophic factor Rattus norvegicus 116-120 29080744-10 2018 DEX treatment decreased serum IL-1beta, TNF-alpha and S-100beta levels and increased BDNF levels. Dexmedetomidine 0-3 brain-derived neurotrophic factor Rattus norvegicus 85-89 29436655-0 2018 Effects of dexmedetomidine post-treatment on BDNF and VEGF expression following cerebral ischemia/reperfusion injury in rats. Dexmedetomidine 11-26 brain-derived neurotrophic factor Rattus norvegicus 45-49 29436655-1 2018 Brain-derived neurotrophic factor (BDNF) and vascular endothelial growth factor (VEGF) serves a significant role in neural protection by activating the phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway, which also was associated with the neuroprotective the treatment with dexmedetomidine (DEX). Dexmedetomidine 282-297 brain-derived neurotrophic factor Rattus norvegicus 0-33 29436655-1 2018 Brain-derived neurotrophic factor (BDNF) and vascular endothelial growth factor (VEGF) serves a significant role in neural protection by activating the phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway, which also was associated with the neuroprotective the treatment with dexmedetomidine (DEX). Dexmedetomidine 282-297 brain-derived neurotrophic factor Rattus norvegicus 35-39 29436655-1 2018 Brain-derived neurotrophic factor (BDNF) and vascular endothelial growth factor (VEGF) serves a significant role in neural protection by activating the phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway, which also was associated with the neuroprotective the treatment with dexmedetomidine (DEX). Dexmedetomidine 299-302 brain-derived neurotrophic factor Rattus norvegicus 0-33 29436655-1 2018 Brain-derived neurotrophic factor (BDNF) and vascular endothelial growth factor (VEGF) serves a significant role in neural protection by activating the phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway, which also was associated with the neuroprotective the treatment with dexmedetomidine (DEX). Dexmedetomidine 299-302 brain-derived neurotrophic factor Rattus norvegicus 35-39 29436655-2 2018 The present study aimed to further explore whether treatment with DEX post-IR increased the expression level of BDNF and VEGF in the rat brain. Dexmedetomidine 66-69 brain-derived neurotrophic factor Rattus norvegicus 112-116 29436655-5 2018 The results indicated that the mRNA expression levels of BDNF and VEGF were higher in the I/R and DEX groups compared with expression levels in the Control group at 6 h and 1 day post-treatment; the levels of BNDF mRNA expression were higher in the DEX group compared with the I/R group. Dexmedetomidine 98-101 brain-derived neurotrophic factor Rattus norvegicus 57-61 29436655-5 2018 The results indicated that the mRNA expression levels of BDNF and VEGF were higher in the I/R and DEX groups compared with expression levels in the Control group at 6 h and 1 day post-treatment; the levels of BNDF mRNA expression were higher in the DEX group compared with the I/R group. Dexmedetomidine 249-252 brain-derived neurotrophic factor Rattus norvegicus 57-61 29436655-6 2018 The levels of BDNF and VEGF protein expression in the I/R and DEX groups were also significantly higher compared with those in the Control group. Dexmedetomidine 62-65 brain-derived neurotrophic factor Rattus norvegicus 14-18 29436655-8 2018 Results from the present study indicated that post-surgical treatment with DEX may increase the expression of BDNF and VEGF following I/R, which may serve a role in nerve protection. Dexmedetomidine 75-78 brain-derived neurotrophic factor Rattus norvegicus 110-114 27571870-9 2016 Dexmedetomidine treatment (0.001-100 microM) of the neurons prior to propofol exposure attenuated the propofol-induced neuronal apoptosis and increased expression levels of BDNF, Bcl-2 and p-CREB compared with the propofol only group. Dexmedetomidine 0-15 brain-derived neurotrophic factor Rattus norvegicus 173-177 27571870-11 2016 These in vitro data indicated that dexmedetomidine exerted direct neuroprotective effects to prevent cultured hippocampal neuronal injury caused by propofol, accompanied by an increase in the levels of p-CREB, Bcl-2 and BDNF. Dexmedetomidine 35-50 brain-derived neurotrophic factor Rattus norvegicus 220-224 24792496-10 2014 Intraperitoneal injections of DEX 40mug/kg for 14 consecutive days markedly reversed the SNI-induced decline of MWT; the activation of microglia was markedly inhibited; in addition, the protein expressions of P2X4Rs, p-p38-MAPK and BDNF were significantly downregulated. Dexmedetomidine 30-33 brain-derived neurotrophic factor Rattus norvegicus 232-236 24792496-11 2014 Thus, DEX could attenuate the neuropathic pain in SNI rats, of which the mechanism might be related to the down-expressed P2X4Rs, p-p38 and BDNF in microglia of spinal dorsal horn. Dexmedetomidine 6-9 brain-derived neurotrophic factor Rattus norvegicus 140-144 23503673-0 2013 Dexmedetomidine ameliorates intracerebral hemorrhage-induced memory impairment by inhibiting apoptosis and enhancing brain-derived neurotrophic factor expression in the rat hippocampus. Dexmedetomidine 0-15 brain-derived neurotrophic factor Rattus norvegicus 117-150 23503673-10 2013 Treatment with dexmedetomidine ameliorated the ICH-induced impairment of short-term and spatial learning memory by suppressing apoptosis and enhancing BDNF and TrkB expression. Dexmedetomidine 15-30 brain-derived neurotrophic factor Rattus norvegicus 151-155 28966649-4 2017 Our results demonstrate that 4 hours after inhaling isoflurane, 20 mug/kg dexmedetomidine visibly mitigated isoflurane-induced neuronal apoptosis, reversed downregulation of brain-derived neurotrophic factor expression, and lessened decreased spatial learning and memory ability in adulthood in the fetal rats. Dexmedetomidine 74-89 brain-derived neurotrophic factor Rattus norvegicus 174-207 28003751-1 2016 The study aimed to explore the effect of dexmedetomidine (DEX) on hippocampal neuron development process and on molecular expression of brain-derived neurotrophic factor (BDNF)-tyrosine receptor kinase B (TrkB) signaling pathway in neonatal rats. Dexmedetomidine 41-56 brain-derived neurotrophic factor Rattus norvegicus 171-175 28003751-1 2016 The study aimed to explore the effect of dexmedetomidine (DEX) on hippocampal neuron development process and on molecular expression of brain-derived neurotrophic factor (BDNF)-tyrosine receptor kinase B (TrkB) signaling pathway in neonatal rats. Dexmedetomidine 58-61 brain-derived neurotrophic factor Rattus norvegicus 171-175 28003751-8 2016 Compared with the control group, the expression of BDNF was significantly upregulated (P<0.05) in the group treated with 100 mumol/L DEX. Dexmedetomidine 136-139 brain-derived neurotrophic factor Rattus norvegicus 51-55 28003751-11 2016 The neuroprotective effect of DEX may be achieved by upregulating the expression of BDNF and phosphorylation level of N-methyl-D-aspartate receptor. Dexmedetomidine 30-33 brain-derived neurotrophic factor Rattus norvegicus 84-88 26655164-8 2016 SIGNIFICANCE: Dexmedetomidine-mediated neuroprotective effects in an in vitro model of cerebral ischemia involve the attenuation of inflammation and oxidative stress and the increment of BDNF expression. Dexmedetomidine 14-29 brain-derived neurotrophic factor Rattus norvegicus 187-191 20613480-7 2010 Spinal infusion of an antibody to BDNF reduced choline acetyltransferase immunoreactivity in the spinal dorsal horn in both normal and SNL rats and abolished facilitation of KCl-evoked acetylcholine release by dexmedetomidine in SNL rats. Dexmedetomidine 210-225 brain-derived neurotrophic factor Rattus norvegicus 34-38